Mesoblast Limited (MESO) Stock Price & How to Invest

Last updated November 2026

Short answer

MESO is the Nasdaq-listed American depositary receipt of Mesoblast Limited, an Australian cell therapy company that crossed from clinical stage to genuine commercial revenue when Ryoncil recorded roughly $115 million of net sales in its first full year on the U.S. market. Owning it means holding a real but still unprofitable specialty biotech at roughly 14 to 15 times trailing sales (October 2026), where most of the remaining value depends on extending one approved product into much larger patient populations. As of October 16, 2026 the ADS closed near $13.47, down about 26% year to date and near its 52-week low.

MESO stock price

As of 2026-11-16, Mesoblast Limited (MESO) last closed at $12.45, down 17.5% over the past year. Over the past 52 weeks it has traded between $11.95 and $20.96.

MESO last close
$12.45
1 day
-6.18%
1 month
-6.25%
1 year
-17.50%
52-week range
$11.95 to $20.96
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Mesoblast Limited's investor relations page. Walnut is informational, not investment advice.

MESO key stats

At $12.45 on November 16, 2026, Mesoblast Limited (MESO) has a market cap of $1.6B.

Market cap
$1.6B
P/E (forward)
27.4
Price to book
2.8
Beta
0.91

Market cap, P/E and yield are measured at the $12.45 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Mesoblast Limited (MESO)?

The last two weeks for Mesoblast Limited, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • MESO closed at $12.45 on November 16, 2026, down 13.8% over the past five trading days (from $14.44).
  • On November 16, 2026, Mesoblast Limited filed a current report (6-K) with the SEC. Read the 6-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Mesoblast Limited (MESO) do?

Mesoblast Limited is a Melbourne-based biopharmaceutical company founded in 2004 by Dr. Silviu Itescu, who still runs it, and it develops allogeneic (off the shelf) mesenchymal stromal cell medicines for severe inflammatory disease. Its lead product, Ryoncil (remestemcel-L-rknd), was approved by the FDA in December 2024 for steroid-refractory acute graft versus host disease in children two months and older, making it the first FDA-approved mesenchymal stromal cell therapy. The regimen is eight intravenous infusions over four weeks at a list price of about $194,000 per infusion, which puts a full course near $1.55 million before rebates, chargebacks and patient assistance. A commercial team of roughly ten representatives sells into about 45 priority transplant centers that handle around 80 percent of U.S. pediatric transplants, and coverage now reaches more than 250 million insured U.S. lives including fee-for-service Medicaid. Mesoblast also earns royalties on TEMCELL, the same cell technology marketed in Japan by licensee JCR Pharmaceuticals, and holds more than 1,000 granted patents and applications running to at least 2044.

The investment picture rests on one launched product and several unapproved ones. Ryoncil net revenue climbed from about $11.3 million in the stub quarter after the late-March 2025 launch to roughly $30.3 million in the March 2026 quarter and about $36 million in the June 2026 quarter, for a full-year fiscal 2026 total near $115 million; the company reported its fiscal year results on August 26, 2026, and Yahoo Finance data show a fiscal 2026 net loss of about $80 million, narrower than the roughly $157 million loss a year earlier. Gross margin is high, with cost of sales of about $7.6 million against roughly $48.7 million of product sales in the December 2025 half, but research and development of about $46.2 million and selling and administrative costs of about $28.5 million in that same half keep the company loss-making. At roughly $13.47 per ADS on October 16, 2026 the market value is close to $1.75 billion, or about 15 times fiscal 2026 Ryoncil revenue, which prices in adult graft versus host disease, chronic low back pain and other indications that have not yet been approved. Ordinary shares outstanding roughly doubled between mid-2022 and mid-2025, so dilution has been a persistent feature of how this company funds itself. In September 2026 the FDA approved a new potency assay used to release and monitor all new commercial Ryoncil lots, a manufacturing step that supports supply as production scales and moves to new facilities.

What's driving Mesoblast Limited (MESO)?

1. Ryoncil's first full year of sales

Ryoncil generated roughly $115 million of net revenue in the fiscal year ended June 30, 2026, its first complete year on the market, with about $66.5 million of that in the second half. Sequential quarters of roughly $30.3 million and $36 million show the ramp continuing rather than flattening after the initial stocking period. Management has described revenue as running ahead of its own launch projections. Analysts tracked by Yahoo Finance expect revenue of about $55 million in the September 2026 quarter and about $267 million for fiscal 2027, which would require the ramp to keep accelerating. The FDA's September 24, 2026 approval of a new potency assay for releasing commercial lots supports manufacturing capacity behind that growth.

2. Label extension into adult graft versus host disease

The approved label covers children only, while the adult steroid-refractory acute GvHD population is roughly three times larger. A registration trial in adults is enrolling, with up to 40 U.S. sites expected to activate that together cover about 60 percent of the roughly 8,500 annual adult allogeneic bone marrow transplants in the United States. Because the manufacturing, sales force and payer coverage already exist, incremental adult volume would flow through a commercial base that is largely built.

3. Rexlemestrocel-L reaching regulatory and trial milestones

Mesoblast received a BLA filing number from the FDA and requested modular review for rexlemestrocel-L in preventing gastrointestinal bleeding in end-stage heart failure patients with a left ventricular assist device, an orphan-designated indication. Separately, the MSB-DR004 registrational Phase 3 trial in chronic low back pain reached its target of at least 300 treated patients in July 2026, and those patients will be followed to a twelve-month pain endpoint. A second and third approved product would change the revenue base materially.

4. A repaired capital structure

In June 2026 Mesoblast drew $50 million from a five-year facility provided by existing shareholder and director Dr. Gregory George, retiring the higher-cost NovaQuest debt and eliminating its near-term maturities. Cash stood at about $103 million at June 30, 2026, and net operating cash spend for fiscal 2026 was roughly $43.8 million, down to about $13.4 million in the second half as product revenue offset spending. The facility is secured against the TEMCELL royalty stream rather than issued as equity, so it did not dilute holders.

What are the risks to Mesoblast Limited (MESO)?

Nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once. The adult GvHD, chronic low back pain, LVAD-related bleeding and Duchenne muscular dystrophy programs are all unapproved, and Mesoblast has a long history of FDA setbacks, including the 2020 complete response letter that preceded a four-year delay to approval. Ordinary shares roughly doubled from about 650 million in mid-2022 to about 1.28 billion in mid-2025, and the company has said it will need additional capital beyond the next twelve months, so further dilution is a reasonable expectation. Book equity of about $575 million at December 31, 2025 is almost entirely intangible assets and goodwill at roughly $569 million, which means the price-to-book ratio understates how little tangible net asset backing there is. Prior management guidance and pipeline timelines have slipped repeatedly, and the share price reflects that skepticism: the ADS fell about 18% over the three months to October 16, 2026 and about 26% year to date, to near its 52-week low of about $13.05. Debt of about $127 million sits against roughly $103 million of cash.

Is MESO a buy or a sell?

We give no verdict on Mesoblast Limited. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Ryoncil's first full year of sales. Ryoncil generated roughly $115 million of net revenue in the fiscal year ended June 30, 2026, its first complete year on the market, with about $66.5 million of that in the second half.

The case against. Nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once.

Read the full bull and bear case on MESO, including what would have to change to break either one. Walnut is not an investment adviser.

Has Mesoblast Limited (MESO) split its stock?

Yes. Mesoblast Limited (MESO) has had one share split in the last 10 years:

  • 1:2 on January 10, 2024, so every share held became 0.5 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of MESO the day before the 1:2 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

How is Mesoblast Limited (MESO) valued?

Market cap, P/E and dividend yield at today's price are in the MESO key stats above. The business figures below come from Mesoblast Limited's reported results as of October 2026 and change when it next reports.

  • Ryoncil net revenue (FY2026, year to June 30, 2026): ~$115M
  • Revenue (TTM, per Yahoo Finance): ~$120M; price to sales ~14.5x
  • Net loss (FY2026): ~$80M, vs ~$157M in FY2025
  • Gross / operating margin: ~80% / about -33%
  • Net operating cash spend (FY2026): ~$43.8M
  • Cash and debt: ~$103M cash, ~$127M debt at June 30, 2026

As of October 2026: Mesoblast reports in U.S. dollars under IFRS even though the parent company's functional currency is the Australian dollar, and its fiscal year ends June 30, so figures quoted as fiscal 2026 cover July 2025 through June 2026. At about $13.47 per ADS on October 16, 2026, the stock trades near 14 to 15 times trailing revenue, down from about 17 times in August as the price fell. Analyst coverage is thin: two analysts in Yahoo Finance's data, with consensus expecting a small loss for fiscal 2027 and a first profit (about $0.46 per ADS) in fiscal 2028.

Who competes with Mesoblast Limited (MESO)?

Drug therapies for graft versus host disease

Ryoncil's closest competition is pharmacological rather than cellular. Incyte's Jakafi (ruxolitinib) is the only other FDA-approved agent for steroid-refractory acute GvHD and is cleared for patients twelve and older, which is precisely the adult segment Mesoblast is now trying to enter. In chronic GvHD, Sanofi's Rezurock (belumosudil) and the Incyte and Syndax product Niktimvo (axatilimab) compete for the same transplant physicians and budgets.

Allogeneic and commercial cell therapy peers

Few companies have taken an off-the-shelf cell therapy all the way to U.S. approval, which is part of Mesoblast's argument. Vericel is the closest commercial comparison in cell therapy, though its MACI and Epicel products are autologous and target cartilage and burns. Atara Biotherapeutics works on allogeneic T-cell products, privately held Orca Bio is developing precision cell grafts intended to prevent GvHD rather than treat it, and Athersys, which pursued a competing allogeneic MSC platform, filed for bankruptcy in 2024, a reminder of how the category has usually ended.

Standard of care in the pipeline indications

For chronic low back pain from degenerative disc disease, rexlemestrocel-L would be measured against physical therapy, epidural steroid injections, spinal fusion surgery and newer non-opioid analgesics such as Vertex's Journavx (suzetrigine), none of which address disc degeneration itself. For gastrointestinal bleeding in LVAD patients, the incumbent is supportive management by transplant cardiologists using devices from Abbott and Medtronic, with no approved preventive drug.

What stocks are similar to Mesoblast Limited (MESO)?

Other names that sit close to MESO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Mesoblast Limited (MESO)

There are three common ways to get MESO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MESO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MESO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Mesoblast Limited (MESO)

Mesoblast now has a marketed product and a repaired balance sheet, and the open question is whether label expansion and the rexlemestrocel-L pipeline can grow into a market value near $1.75 billion (October 2026), down from about $2.1 billion in August.

More on Mesoblast Limited (MESO)

Whether MESO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MESO a buy or a sell?, and where the stock could go from here in the MESO stock forecast.

For income investors, whether MESO pays a dividend and how the payout looks is covered in does MESO pay a dividend? And to weigh MESO against a peer, read the full side-by-side comparisons: MESO vs INCY and MESO vs SNY.

Wondering how MESO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Mesoblast Limited

Ask Walnut's AI anything about MESO and see how it fits what you own.

FAQ

What does Mesoblast do, and what is Ryoncil?

+

Mesoblast develops allogeneic, or off the shelf, mesenchymal stromal cell medicines that dampen severe inflammation. Ryoncil (remestemcel-L-rknd) is its one approved product, cleared by the FDA in December 2024 for steroid-refractory acute graft versus host disease in children two months and older. It was the first mesenchymal stromal cell therapy ever approved in the United States, and it is given as eight intravenous infusions over four weeks.

Is MESO an ADR, and how many ordinary shares does each one represent?

+

Yes. MESO is a sponsored American depositary share listed on the Nasdaq Global Select Market, and each ADS currently represents ten Mesoblast ordinary shares. The ratio was five ordinary shares per ADS until it was changed to ten during the 2024 fiscal year, so per-ADS price history from before that change is not directly comparable. Average volume runs around 170,000 to 190,000 ADS a day, so this is a normally traded Nasdaq listing rather than a thin over-the-counter quote.

What is the difference between MESO on Nasdaq and MSB on the ASX?

+

They are claims on the same company. MSB is the Australian Securities Exchange line in ordinary shares and Australian dollars, and it is the primary listing. MESO is the Nasdaq ADS line in U.S. dollars, with each ADS backed by ten ordinary shares held by a depositary bank. Most U.S. brokers, including those Walnut connects to, will only offer the MESO line, and the depositary charges periodic fees against ADS holders.

What currency does Mesoblast report its financials in?

+

U.S. dollars. Mesoblast prepares its accounts under IFRS with U.S. dollars as its presentation currency, even though the parent company's functional currency is the Australian dollar. Its fiscal year ends June 30, so a reference to fiscal 2026 means the twelve months from July 2025 to June 2026.

How much revenue is Ryoncil actually generating?

+

Ryoncil net revenue was about $115 million for the fiscal year ended June 30, 2026, its first full year on the market, with roughly $36 million in the June quarter and $30.3 million in the March quarter. That is real product revenue from U.S. sales, not milestone or licensing income. A small separate royalty stream, roughly $2.7 million in the December 2025 half, comes from TEMCELL sales in Japan by licensee JCR Pharmaceuticals.

Is Mesoblast profitable, and how much cash does it hold?

+

Not yet. Yahoo Finance data show a net loss of about $80 million for the fiscal year to June 30, 2026, down from about $157 million a year earlier, after a loss of about $40.2 million in the six months to December 31, 2025. Cash was roughly $103 million at June 30, 2026, against about $127 million of debt, and net operating cash spend for fiscal 2026 was about $43.8 million, improving to roughly $13.4 million in the second half as Ryoncil sales scaled. The auditors issued a clean opinion on the fiscal 2025 accounts with no going-concern qualification.

What milestones are ahead for Mesoblast?

+

The registration trial for Ryoncil in adults with steroid-refractory acute GvHD is enrolling, targeting a population about three times the size of the approved pediatric one. The MSB-DR004 registrational Phase 3 trial of rexlemestrocel-L in chronic low back pain reached its 300-patient target in July 2026 and now runs to a twelve-month endpoint. Mesoblast has also requested modular BLA review for rexlemestrocel-L in LVAD-related gastrointestinal bleeding and received IND clearance to start a registrational trial of Ryoncil in Duchenne muscular dystrophy in children aged five to nine.

Has Mesoblast faced securities litigation?

+

It has, though the known cases are resolved. A U.S. securities class action was filed in the Southern District of New York in 2020 covering purchasers between April 2019 and October 2020, following the FDA complete response letter on remestemcel-L. A separate shareholder class action in the Federal Court of Australia, filed in 2022, settled for A$26.5 million with approval granted on December 13, 2024, funded entirely by insurers and with no admission of liability. Mesoblast's most recent annual report and half-year report disclose no pending securities class action.

How has MESO stock performed in 2026?

+

As of October 16, 2026, the MESO ADS closed near $13.47, down about 25.8% year to date and about 25.5% over one year, close to its 52-week low of about $13.05 (the high was $21.50). It fell about 11% in the month to October 16 even after the FDA approved a new Ryoncil potency assay on September 24. Past performance does not predict future returns.

What did the FDA approve for Mesoblast in September 2026?

+

On September 24, 2026 Mesoblast announced FDA approval of a new potency assay, the T-cell Proliferation Inhibition BioAssay, used to release and monitor the stability of all new commercial Ryoncil lots. It runs alongside existing potency tests and is designed to catch potency changes from process changes or production at new facilities. It is a manufacturing approval, not a new indication.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Mesoblast Limited's investor relations page or your broker before making investment decisions.